Abstract
Prolyl oligopeptidase (POP), a serine protease highly expressed in the brain, has recently emerged as an enticing therapeutic target for the treatment of cognitive and neurodegenerative disorders. However, most reported inhibitors suffer from short duration of action, poor protease selectivity, and low blood-brain barrier (BBB) permeability, which altogether limit their potential as drugs. Here, we describe the structure-based design of the first irreversible, selective, and brain-permeable POP inhibitors. At low-nanomolar concentrations, these covalent peptidomimetics produce a fast, specific, and sustained inactivation of POP, both in vitro and in human cells. More importantly, they are >1,000-fold selective against two family-related proteases (DPPIV and FAP) and display high BBB permeability, as shown in both lipid membranes and MDCK cells.
Citations
Jul 20, 2018·Angewandte Chemie·Pablo Martín-Gago, Christian A Olsen
Sep 26, 2019·Current Protein & Peptide Science·Anna J Kiss-SzemánDóra K Menyhárd
Apr 7, 2020·Journal of Biomolecular Structure & Dynamics·Shweta SharmaMymoona Akhter
Aug 23, 2019·Nature Communications·Ruting XuSaihu Liao
Jul 4, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Arduino A MangoniPaula A C Gomes
Apr 2, 2019·Journal of Biomolecular Structure & Dynamics·Apeksha ShrivastavaMymoona Akhter
Dec 10, 2019·Journal of Biomolecular Structure & Dynamics·Shweta SharmaMymoona Akhter
Dec 17, 2020·Biomedicines·Giovanna CasiliEmanuela Esposito
May 21, 2020·Biochimica Et Biophysica Acta. General Subjects·Yakov E DunaevskyElena N Elpidina
Apr 27, 2021·Evidence-based Complementary and Alternative Medicine : ECAM·Apoorva M KulkarniKeun Woo Lee
Jun 9, 2021·ChemMedChem·Fabian H KnaupFelix Hausch
Jul 30, 2021·Frontiers in Pharmacology·Jasmin GattringerRoland Hellinger
Aug 6, 2021·Chemical Science·Tao ZhongJiang Weng
Apr 3, 2020·Journal of Chemical Information and Modeling·Lin WeiJian Wan
Aug 13, 2021·Angewandte Chemie·Xingliang NieSaihu Liao